ONO Pharma logo
「ONO Pharma logo」熱門搜尋資訊
「ONO Pharma logo」文章包含有：「ONOPHARMACEUTICALCO.」、「ONOPHARMAUSA」、「OnoPharmaceutical」、「OnoPharmaFoundation」、「AboutUs」、「ONOPharma」、「ONOPHARMAUSA」、「ONOPHARMACEUTICAL」、「Japan'sOnoPharmatobuyU.S.drugmakerDecipherafor...」
查看更多
ONO PHARMACEUTICAL CO.
https://www.ono-pharma.com
We want to deliver new drugs to the world with a wish. For more than 300 years since its foundation in 1717, working for people's health.
ONO PHARMA USA
https://us.ono-pharma.com
ONO PHARMA USA is a pharmaceutical company dedicated to developing innovative medicines across oncology, neurology, immunology, and specialty.
Ono Pharmaceutical
https://en.wikipedia.org
Ono Pharmaceutical Co., Ltd is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in ...
Ono Pharma Foundation
https://www.onofound.org
The Ono Pharma Foundation was established to support academic research in relevant scientific fields, which have the potential of making significant impact ...
About Us
https://www.onofound.org
The Ono Pharma Foundation was established to support academic research in relevant scientific fields, which have the potential of making significant impact.
ONO Pharma
https://www.navigatingpcnsl.co
ONO Pharma Logo. Home Understanding R/R PCNSL Current Treatment Challenges ... ONO Pharma Logo. ©2023 ONO PHARMA USA. INC. All Rights Reserved. 12/2023 ...
ONO PHARMA USA
https://www.linkedin.com
ONO PHARMA USA is the US subsidiary of ONO PHARMACEUTICAL CO, LTD., an R&D-oriented pharmaceutical company founded in 1717, with headquarters in Osaka, Japan.
ONO PHARMACEUTICAL
https://www.domaintherapeutics
Ono Pharmaceutical.,Ltd signed a collaboration agreement to discover novel small molecules targeting G-Protein Coupled Receptors in a metabolic disease area.
Japan's Ono Pharma to buy U.S. drugmaker Deciphera for ...
https://asia.nikkei.com
Ono Pharmaceutical plans to purchase an American cancer drug maker for $2.4 billion in its largest acquisition yet, seeking growth with new-drug candidates.